Federal grant · project grant (b)
Biology and Genetics of Metastatic Disease - Biology and Genetics of Metastatic Disease My Laboratory Studies the Molecular Alterations That Contribute to Metastasis Formation, a Poorly Understood Process and Primary Cause of Solid Cancer Deaths. It Has Long Been Thought That Metastasis Is Caused by Somatic Metastasis Driver Mutations—postulated Alterations That Have Yet to Be Identified. by Showing That Levels of Specific Micrornas Become Altered in Metastatic Tumors and Identifying Their Target Genes, My Lab Identified and Characterized Critical Pathways and Processes Underlying Metastasis Formation. by Studying Germline Variants of One Such Target Metastasis Gene, We Discovered That Metastatic Potential Can Also Pre- Date Tumor Formation and Be Genetically Inherited—revealing an Unanticipated Genetic Underpinning for Metastasis and Opening Up a New Direction for the Field. Specifically, We Determined That Two Common Human Germline Variants of the Secreted Glycoprotein Apoe Promote or Suppress Metastasis in Melanoma, With Recent Data Suggesting This Principle May Apply to Additional Cancers. Apoe Signaling Was Found to Govern Vascular and Immune Interactions as Well as Cellular Invasiveness That Collectively Contribute to Metastasis Formation. These Insights Have Significant Translational Potential and Formed the Basis of Clinical Trials That Are Providing Proof-of-concept for ‘metastasis Targeting Therapy’, Where Multiple Metastasis Regression Responses Were Observed in Advanced Stage Patients for Whom Standard of Care and Immunotherapy Treatments Had Failed. Going Forward, We Will Use Allelic Variants of Apoe as Powerful Genetic Entry Points to Understand the Molecular Events Underlying Metastasis Formation, Where We Will Define How Apoe Signals Are Received by Cells and How Apoe Mediates Intracellular Events. We Will Also Extend the Concept of Hereditary Metastasis Genetics to Additional Cancers and Genes, Applying Our Reverse Genetic and Mouse Modeling Approaches to Breast and Colorectal Cancer Metastasis. to Achieve This Understanding, We Will Employ Innovative Optical, Physiological, Genetic Modeling and Screening Methods to Interrogate Mouse and Human Metastatic Transitions. This Award Will Enable Our Group to Establish the First Genetically Guided Framework for Understanding the Molecular Mechanisms Governing Metastasis Formation—enabling New Avenues for Its Therapeutic Treatment and Prevention.
Committed
$3.7 Million
Paid out
$3.2M
87%
Committed, not yet paid
$461.5K
13%
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.